Aptevo Therapeutics Files 8-K with Corporate Updates

TL;DR

APVO filed an 8-K for corporate updates and financials.

AI Summary

Aptevo Therapeutics Inc. filed an 8-K on December 3, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, incorporated in Delaware, is in the pharmaceutical preparations industry and is headquartered in Seattle, Washington.

Why It Matters

This filing indicates routine corporate actions and financial reporting, providing transparency to investors about the company's administrative and financial status.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting corporate actions and financial statements, not indicating any immediate significant operational or financial risks.

Key Numbers

• 001-37746 — SEC File Number (Identifies the company's filing with the SEC.)
• 81-1567056 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — Registrant
• December 03, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 2401 4th Avenue Suite 1050 (address) — Principal Executive Offices
• Seattle, Washington (location) — City and State of Principal Executive Offices
• 98121 (zip_code) — Zip Code of Principal Executive Offices
• (206) 838-0500 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar

Filing Documents

• apvo-20241203.htm (8-K) — 46KB
• apvo-ex3_1.htm (EX-3.1) — 20KB
• 0000950170-24-132855.txt ( ) — 189KB
• apvo-20241203.xsd (EX-101.SCH) — 26KB
• apvo-20241203_htm.xml (XML) — 5KB

03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. (a) Amendment of Articles of Incorporation to Effect Reverse Stock Split On October 25, 2024, Aptevo Therapeutics Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting") at which the Company's stockholders approved a series of alternate amendments to the Company's Amended and Restated Certificate of Incorporation to effect, at the option of the Board of Directors of the Company (the "Board"), a reverse split of the Company's common stock at a ratio ranging from 1-for-5 to 1-for-37, inclusive, with the effectiveness of one of such amendments and the abandonment of the other amendments, or the abandonment of all amendments, to be determined by the Board in its sole discretion following the Special Meeting. The specific 1-for-37 reverse split ratio was subsequently approved by the Board on October 25, 2024. On September 23, 2024, the Board approved an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of its common stock at the reverse split ratio of 1-for-37 (the "Reverse Stock Split"). Accordingly, on December 2, 2024, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the "Amendment") with the Secretary of State of the State of Delaware to effect the Reverse Stock Split. The Amendment was effective at 5:01 p.m. Eastern Time on December 3, 2024 (the "Effective Time"). The Amendment provides that, at the Effective Time, every 37 shares of the Company's issued and outstanding common stock was automatically combined into one issued and outstanding share of common stock, without any change in par value per share. As a result of the Reverse Stock Split, proportionate adjustments will be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all then outstanding stock options, restricted

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment of Amended and Restated Certificate of Incorporation of Aptevo Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Forward-Looking Statements

Forward-Looking Statements

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: December 3, 2024 By: /s/ Marvin L. White President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR